The 4G/4G genotype of the PAI-1 (Serpine-1) 4G/5G polymorphism is associated with decreased lung allograft utilization

American Journal of Transplantation

Volumn 12, Issue 7, 2012, Pages 1848-1854

  Sapru, Anil ^a   Zaroff, J G ^b   Pawlikowska, L ^a   Liu, K D ^a   Khush, K K ^c   Baxter Lowe, L A ^a   Hayden, V ^d   Menza, R L ^e   Convery, M ^a   Lo, V ^a   Poon, A ^a   Kim, H ^a   Young, W L ^a   Kukreja, J ^a   Matthay, M A ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Kaiser Permanente ^*  (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d California Transplant Donor Network   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

PAI 1; Polymorphisms; Transplantation

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ALLELE; ARTICLE; CAUCASIAN; DNA POLYMORPHISM; FEMALE; FIBRINOLYSIS; GENDER; GENETIC ASSOCIATION; GENOTYPE; HUMAN; INDEL MUTATION; LUNG; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; OXYGENATION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES;

ADULT; COHORT STUDIES; FEMALE; GENOTYPE; HUMANS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84863185772     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.03996.x     Document Type: Article

References (28)

1. Ojo AO, Heinrichs D, Emond JC, et al. Organ donation and utilization in the USA. Am J Transplant 2004; 4(Suppl 9): 27-37. (Pubitemid 38858993)
2. Edwards LB, Keck BM. Thoracic organ transplantation in the US. Clin Transpl 2002: 29-40.
3. Power BM, Van Heerden PV. The physiological changes associated with brain death-current concepts and implications for treatment of the brain dead organ donor. Anaesth Intensive Care 1995; 23: 26-36.
4. Salim A, Martin M, Brown C, Belzberg H, Rhee P, Demetriades D. Complications of brain death: Frequency and impact on organ retrieval. Am Surg 2006; 72: 377-381. (Pubitemid 46940731)
5. Smith M. Physiologic changes during brain stem death-lessons for management of the organ donor. J Heart Lung Transplant 2004; 23(9 Suppl): S217-222. (Pubitemid 39286199)
6. Wilkes DS, Egan TM, Reynolds HY. Lung transplantation: Opportunities for research and clinical advancement. Am J Respir Crit Care Med 2005; 172: 944-955. (Pubitemid 41476530)
7. Bredbacka S, Edner G. Soluble fibrin and D-dimer as detectors of hypercoagulability in patients with isolated brain trauma. J Neurosurg Anesthesiol 1994; 6: 75-82. (Pubitemid 24094177)
8. Pathak A, Dutta S, Marwaha N, Singh D, Varma N, Mathuriya SN. Change in tissue thromboplastin content of brain following trauma. Neurol India 2005; 53: 178-182. (Pubitemid 41595391)
9. Stein SC, Smith DH. Coagulopathy in traumatic brain injury. Neurocrit Care 2004; 1: 479-488. (Pubitemid 41278339)
10. Ware LB, Fang X, Wang Y, Babcock WD, Jones K, Matthay MA. High prevalence of pulmonary arterial thrombi in donor lungs rejected for transplantation. J Heart Lung Transplant 2005; 24: 1650-1656. (Pubitemid 41396466)
11. Ware LB, Wang Y, Fang X, et al. Assessment of lungs rejected for transplantation and implications for donor selection. Lancet 2002; 360: 619-620. (Pubitemid 35232198)
12. Akasaka S, Nishi H, Aoe M, Date H, Andou A, Shimizu N. The effects of recombinant tissue-type plasminogen activator (rt-PA) on canine cadaver lung transplantation. Surg Today 1999; 29: 747-754. (Pubitemid 29403977)
13. Horrevoets AJ. Plasminogen activator inhibitor 1 (PAI-1): In vitro activities and clinical relevance. Br J Haematol 2004; 125: 12-23. (Pubitemid 38453272)
14. Sapru A, Curley MA, Brady S, Matthay MA, Flori H. Elevated PAI-1 is associated with poor clinical outcomes in pediatric patients with acute lung injury. Intensive Care Med 2010; 36: 157-163.
15. Ware LB, Matthay MA, Parsons PE, Thompson BT, Januzzi JL, Eisner MD. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med 2007; 35: 1821-1828. (Pubitemid 47220354)
16. Eriksson P, Kallin B, van 't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995; 92: 1851-1855.
17. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268: 10739-10745. (Pubitemid 23162248)
18. Sapru A, Hansen H, Ajayi T, et al. 4G/5G polymorphism of plasminogen activator inhibitor-1 gene is associated with mortality in intensive care unit patients with severe pneumonia. Anesthesiology 2009; 110: 1086-1091.
19. Song Y, Lynch SV, Flanagan J, et al. Increased plasminogen activator inhibitor-1 concentrations in bronchoalveolar lavage fluids are associated with increased mortality in a cohort of patients with Pseudomonas aeruginosa. Anesthesiology 2007; 106: 252-261. (Pubitemid 46185169)
20. Yende S, Angus DC, Ding J, et al. 4G/5G plasminogen activator inhibitor-1 polymorphisms and haplotypes are associated with pneumonia. Am J Respir Crit Care Med 2007; 176: 1129-1137. (Pubitemid 350223759)
21. Hsu TM, Kwok PY. Homogeneous primer extension assay with fluorescence polarization detection. Methods Mol Biol 2003; 212: 177-187.
22. Kathiresan S, Gabriel SB, Yang Q, et al. Comprehensive survey of common genetic variation at the plasminogen activator inhibitor-1 locus and relations to circulating plasminogen activator inhibitor-1 levels. Circulation 2005; 112: 1728-1735. (Pubitemid 41368148)
23. Idell S, James KK, Levin EG, et al. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest 1989; 84: 695-705. (Pubitemid 19197006)
24. Vadasz I, Morty RE, Olschewski A, et al. Thrombin impairs alveolar fluid clearance by promoting endocytosis of Na+,K+-ATPase. Am J Respir Cell Mol Biol 2005; 33: 343-354. (Pubitemid 41416284)
25. Hoekstra T, Geleijnse JM, Schouten EG, Kluft C. Plasminogen activator inhibitor-type 1: Its plasma determinants and relation with cardiovascular risk. Thromb Haemost 2004; 91: 861-872. (Pubitemid 38647488)
26. Cardon LR, Bell JI. Association study designs for complex diseases. Nat Rev Genet 2001; 2: 91-99. (Pubitemid 33674000)
27. Ding J, Nicklas BJ, Fallin MD, et al. Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke. Am Heart J 2006; 152: 1109-1115. (Pubitemid 44872986)
28. Hermans PW, Hibberd ML, Booy R, et al. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 1999; 354: 556-560. (Pubitemid 29381370)